Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

Table 4

Adverse events associated with the commercially available TKIs used in thyroid cancer.

Adverse event	Sorafenib (%)		Sunitinib (%)		Pazopanib (%)
	All grade	≥grade 3	All grade	≥grade 3	All grade	≥grade 3
Hypertension	17	4	30	12	40	4
CHF or LVEF decline	1.7	NR	13	3	<1%	NR
Proteinuria	NR	NR	NR	NR	9	<1
Hand-foot skin reaction	30	6	29	6	6	NR
Stomatitis	NR	NR	30	1	4	NR
Anorexia	16	<1	34	2	22	2
Weight loss	10	<1	12	<1	52	3.5
Diarrhea	43	2	61	9	52	3.5
AST elevation	NR	NR	56	2	53	7.5
ALT elevation	NR	NR	51	2.5	53	12
Fatigue	37	5	54	11	19	2
Hypothyroidism	NR	NR	14	2	7	NR
Arterial thromboembolism	2.9	NR	NR	NR	3	2
Hemorrhage/bleeding (all sites)	15	3	30	3	13	2

CHF: congestive heart failure; LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NR: not reported. table adapted from [115].